ArticleChemistryOpen2026
Synthesis, X-Ray Analysis, Anticancer Activity, Computational, and in Silico Studies of New Thiophene Pyrazole Conjugates.
Article in ChemistryOpen, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
A convenient synthesis of two new thiophene-appended pyrazoles, 8a and 8b, from thiophene derivative 3 is reported. The structures of the synthesized compounds were confirmed by infrared, nuclear magnetic resonance, and mass spectroscopy analysis, while compound 8a was further confirmed by single-crystal X-ray diffraction and computational studies. The crystal structure of 8a revealed a nonplanar conformation stabilized by NH···O hydrogen bonding and a weak CH···O/N contacts. Hirshfeld surface analysis of 8a showed that H···H contacts dominate the packing, accounting for 52.8%. Density functional theory calculations showed a highest occupied molecular orbital-lowest unoccupied molecular orbital gap of 3.999 eV, indicating a moderate electronic stability with charge transfer ability. The in vitro antitumor activity of the synthesized compounds was evaluated against liver (HepG2), breast (MCF-7), and colorectal (HCT-116) cancer cell lines, using the sulforhodamine B (SRB) assay. Compound 3 showed the highest activity against MCF-7 (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.